30.1 C
New York

Tag: changing

The Top 7 Marketing Challenges Faced Globally in 2022 [HubSpot Data + Expert Tips]

Every marketer faces different challenges. And, ever since 2020, the ways we've had to pivot, adjust campaigns, and address challenges has been unlike anything many of us have had to do before.

Essex Bio-Technology Announces 2021 Financial Results

Tag Template - News Hub PRO

HONG KONG, Mar 22, 2022 - (ACN Newswire) - Essex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.

Highlights
-- The group's turnover surged 67.4% to HK$1,637.7 million, Profit-After-Tax lifted 58% to HK$346.0 million;

-- Sales coverage increased to around 10,500 hospitals and 2,110 pharmaceutical stores in the PRC;

-- Obtained an approval for the registration and commercialisation of the preservative-free unit-dose Moxifloxacin Hydrochloride Eye Drops in the PRC;

-- Significant progress in R&D program, 15 R&D programs in the pre-clinical to clinical stage, out of which 3 ophthalmology programs are in clinical stage as the below:
SkQ1 eye drops, second phase 3 clinical trial (US FDA) (VISTA-2) topline data released on 24 February 2021;
Azithromycin eye drops, ongoing review by external key opinion leaders (National Medical Products Administration ("NMPA") in the PRC);
Bevacizumab intravitreal injection for wet-AMD, phase 3 clinical trial (US FDA, European Medicines Agency, Therapeutic Goods Administration and NMPA in the PRC);

-- Holds a total of 44 patent certificates or authorisation letters: 35 invention patents, 4 utility model patents and 5 design patents;

-- Completed the acquisition of IP rights relating to R&D, production and MAH of Shilishun Iodized Lecithin Capsules.

Significant progression in Financial Performances

Essex achieved significant progression and encouraging performances amid the COVID-19 pandemic and macro uncertainties. For the year ended 31 December 2021, the Group recorded a turnover growth of 67.4% to approximately HK$1,637.7 million as compared to approximately HK$978.1 million in 2020, indicating a strong recovery to the pre-COVID-19 operating level. In tandem with the increase of turnover, the Group achieved an increase of 58% in after-tax profit to approximately HK$346.0 million as compared to approximately HK$218.9 million in 2020.

Turnover of Ophthalmology and Surgical Segments Surged 60.6% and 72.6% respectively
The Group's turnover is primarily made up from the segments of Ophthalmology and Surgical (wound care and healing). The core products that are of current growth driver under each segment are:

1. Ophthalmology - Beifushu series (Beifushu eye drops, Beifushu eye gel and Beifushu unit-dose eye drops), Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Moxifloxacin Hydrochloride Eye Drops and Shilishun(Iodized Lecithin Capsules); and

2. Surgical (Wound care and healing) - Beifuji series (Beifuji spray, Beifuji lyophilised powder and Beifuxin gel), Carisolv dental caries removal gel, Dr. YaDian mouth wash and Yi Xue An Granules.

The sectoral turnover of Ophthalmology and Surgical is approximately 41.1% and 58.9% of the Group's turnover, respectively. The combined turnover of the Group's flagship biologics, Beifushu series and Beifuji series, the basic fibroblast growth factor (bFGF) based biologic drugs, represented about 84.3% of the Group's total turnover, of which Beifushu series and Beifuji series accounted for 26.1% and 58.2% of the Group's turnover, respectively. The remaining 15.7% of the Group's turnover is mainly contributed from sales of Tobramycin Eye Drops, Levofloxacin Eye Drops, Sodium Hyaluronate Eye Drops, Moxifloxacin Hydrochloride Eye Drops, Shilishun Iodized Lecithin Capsules, Carisolv dental caries removal gel, Dr. YaDian mouth wash and Yi Xue An Granules, collectively. Ophthalmology segment contributed approximately HK$673.3 million to the Group's turnover for the year ended 31 December 2021, representing an increase of 60.6% as compared to approximately HK$419.2 million in 2020. Surgical segment recorded a total turnover of approximately HK$964.4 million for the year ended 31 December 2021, representing an increase of 72.6% as compared to approximately HK$558.9 million in 2020. The increase was attributable to the resumption of clinical operations in hospitals to normalcy in the PRC and the expansion of sales.

The selling of Xalatan Eye Drops and Xalacom Eye Drops would be discontinued in 2022 that contributed approximately 2% to the Group's gross profit for the year ended 31 December 2021.

The Board proposed a final dividend of HK$0.055 (2020: HK$0.05) per ordinary share to be approved at the upcoming annual general meeting of the Company.

Mr. Patrick Ngiam, Chairman of Essex, said, "2021 has been a year full of diverse challenges. Our part of the world has been affected by extended lockdowns and border closures under COVID zero regime, even as other regions begun to reopen. Despite yet another difficult year inflicted by the pandemic of COVID-19 on us all, the tenacity, drive and leadership in our DNA was able to deliver greater stakeholder value. The Group has achieved significantly improved financial performances in the financial year ended 31 December 2021. This is a testament that the Group's business is resilient and was able to recover swiftly to the pre-COVID-19 level after the normalcy of the clinical operations of hospitals resumed in the PRC since September 2020."

Significant Business Development Activities

The Group is committed to pragmatically investing in new products and technologies to strengthen the Group's product and R&D pipeline as near to mid-term growth driver in ophthalmology and long-term plan for new therapeutics in oncology. During the year under review, major investments in ophthalmic products are outlined as follows:

Investment in Ophthalmology

Significant progress for SkQ1's second phase 3 clinical trial
In 2018, the Group entered into a co-development agreement with Mitotech S.A. ("Mitotech") and Mitotech LLC for the United States Food and Drug Administration (the "US FDA") phase 3 clinical trial of an ophthalmic solution containing SkQ1 for dry eye disease. As disclosed in the announcement of the Company dated 24 February 2021, positive outcome was achieved during second phase 3 clinical trial (VISTA-2). The clinical trial study repeated statistically significant positive results on key predefined secondary end-point (Central Corneal Fluorescein Staining). The Board is enthusiastic about the read-out of clearing of central staining of the cornea (defined as zero staining in central cornea), which reveals the potential of SkQ1 in addressing oxidative stress in dry eye diseases. Following the positive trial outcome of VISTA-2, Mitotech has planned a pivotal trial (VISTA-3), which will commence once Mitotech's management team has fully assessed there is no potential disruption to trial centres and patient recruitment during the ongoing COVID-19 pandemic. However, recent developments in Ukraine have led to governments and industries reacting to business relationships with Russia in a way that could potentially induce delays in Mitotech's VISTA clinical trial program.

HLX04-O approved for phase 3 clinical trial
In 2020, the Group entered into a co-development and exclusive license agreement with Shanghai Henlius Biotech, Inc. to co-develop a pharmaceutical product that contains an anti-vascular endothelial growth factor ("anti-VEGF") as a drug substance, which is intended for the treatment of exudative (wet) age-related macular degeneration ("wet-AMD"). As at the date of 22 March 2022, the recombinant anti-VEGF humanised monoclonal antibody injection HLX04-O ("HLX04-O") for the treatment of wet-AMD has been approved to commence the phase 3 clinical trial in Australia, the United States, Singapore, Russia, Serbia and European Union countries such as Hungary, Spain, Latvia, the Czech Republic and Poland. Also, the first patient has been dosed in a phase 3 clinical study for HLX04-O for the treatment of wet-AMD in the PRC.

Ophthalmology business is expected to be further strengthened by the acquisition of Shilishun Iodized Lecithin Capsules

The successful acquisition of IP rights relating to R&D, production and MAH of Shilishun Iodized Lecithin Capsules will enable the Group to strengthen its ophthalmology business.

Market Development

Robust Market Access Capability
Over the years, the Group has been relentlessly investing in establishing and strengthening its market access capability. As at 31 December 2021, the Group maintains a network of 43 regional sales offices in the PRC and a total number of about 1,265 sales and marketing representatives, out of which 64% are full-time employees and 36% are on contract basis or from appointed agents.

More Extensive Healthcare Network for Product Prescription
During the year under review, the Group's therapeutic products are being prescribed in more than 10,500 hospitals and medical providers, coupled with approximately 2,110 pharmaceutical stores, which are mainly located in the major cities, provinces and county cities in the PRC.

Further Investments to Strengthen Competitiveness and Customer Base
For achieving a sustainable traction on growth for currently marketed products as well as for near-term to mid-term new products being commercialised, the Group initiated investments to improve its competitiveness and widen its customer base under the following plans:

-- Investing in clinical observation programs for affirming additional clinical indications of its commercialised products;
-- Reaching out to market in lower-tier cities;
-- Cultivating pharmaceutical stores, where possible, as complementary sales channel; and
-- Building on-line platform for medical consultation and e-prescription for patients with chronic diseases under its healthtech initiative.

The Group has initiated its market access expansion to Southeast Asian countries by setting up a base and expanded its presence in Singapore since 2020.

Research and Development

The Group renewed its R&D's vision, emphasising the dedication to science and innovation, with a mission to develop therapeutics that would meet unmet clinical and/or commercial needs. The Group concurrently kick-started a 5-year (2021 to 2025) R&D's development plan to further strengthen its R&D capability and its position in Ophthalmology.

As at 31 December 2021, there are 15 R&D programs in the pre-clinical to clinical stage, out of which 3 ophthalmology programs are in clinical stage. The 3 ophthalmology programs listed below are targeted as mid-term growth driver.

1. EB11-18136P: SkQ1 eye drops, second phase 3 clinical trial (US FDA) (VISTA-2) topline data released on 24 February 2021

2. EB11-15120P: Azithromycin eye drops, ongoing review by external key opinion leaders (National Medical Products Administration ("NMPA") in the PRC)

3. EB12-20145P: Bevacizumab intravitreal injection for wet-AMD, phase 3 clinical trial (US FDA, European Medicines Agency, Therapeutic Goods Administration and NMPA in the PRC)

As at the date of this announcement, the Group has obtained a total of 44 patent certificates or authorisation letters: 35 invention patents, 4 utility model patents and 5 design patents.

The Group currently has diversified its R&D resources to multiple research sites in Zhuhai (PRC), Boston (United States), London (United Kingdom) and Singapore which supports not only our pursuit for new therapeutics but also our acquisition of global talent.

Prospects

Looking ahead, the Group will continue to monitor the circumstances under the uncertainty of COVID-19 in 2022. Its strong team spirit and dynamic leadership have provided it with the capacity to navigate these turbulent times, and capture any opportunities in the ever changing world. The Group remains highly dynamic in delivering positive results in the coming year.

"COVID-19 remains a major concern in 2022 globally. We continue to monitor the situation and will take appropriate actions to overcome any unforeseen challenges. Barring the unforeseen circumstance, the Group remains focus on executing its plans and delivering progressive results. I would like to take this opportunity to express my sincere gratitude to all stakeholders, business associates and valued customers for the trust, support and cooperation accorded to us, and each and every member of the Group for their relentless efforts rendered in shaping the Group into being a progressive and promising pharmaceutical player.", said Mr. Patrick Ngiam.

Full version of Essex's FY2021 Annual Results Announcement can be downloaded at: https://www1.hkexnews.hk/listedco/listconews/sehk/2022/0322/2022032200780.pdf

About Essex Bio-Technology Limited (Stock Code: 1061.HK)
Essex Bio-Technology Limited is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialised biologics marketed in China since 1998. Additionally, it has a portfolio of commercialised products of preservative-free unit-dose eye drops and Shilishun Iodized Lecithin Capsules etc.. The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology and Dermatology, which are marketed and sold through approximately 10,500 hospitals and managed directly by its 43 regional sales offices in China. Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields and indications.

Media Enquiry:
Strategic Financial Relations Limited (Website: http://www.sprg.com.hk)
Shelly Cheng +852 2864 4857 shelly.cheng@sprg.com.hk
Yan Li +852 2114 4320 yan.li@sprg.com.hk
Jill Cheung +852 2114 4870 jill.cheung@sprg.com.hk
Media: media@essex.com.cn

Investor Enquiry:
Investor Relations: investors@essex.com.cn


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comEssex Bio-Technology Ltd ("Essex" or the "Group", Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021.

Artificial Intelligence as a Catalyst to Accelerate Financial Inclusion

The use of Artificial Intelligence (AI) in financial services is all over the news, with some reports estimating it to be a US$450 billion opportunity. But what’s the real story

The post Artificial Intelligence as a Catalyst to Accelerate Financial Inclusion appeared first on Fintech Singapore.

Technology changing last-mile delivery sector

COVID-19 has accelerated the use of technology across almost every industry and sector, with... Read more »

The post Technology changing last-mile delivery sector appeared first on Logistics Business® Magazine.

Women on the verge of transformational leadership

When IBM launched its first women in leadership study in 2019, the research revealed a persistently glaring gender gap in the global workplace. At that time, only 18% of senior leadership positions worldwide were held by women. And only 12% of organizations surveyed were going above and beyond their peers to address it head on […]

The post Women on the verge of transformational leadership appeared first on IBM Business Operations Blog.

How is the ‘Mesh’ Resolving Bottlenecks of Data Management

If you are stuck with dumping data into warehouses and lakes then you are most likely not prepared for what’s coming up next. We are sliding into Web 3.0, an era of decentralization that trusts local ownership. This era is changing data as we know it. It has begun to testify its worth with products […]

The post How is the ‘Mesh’ Resolving Bottlenecks of Data Management appeared first on SmartData Collective.

Tag Template - News Hub PRO

Renewable Power Finance for Non-Finance Professionals – A Brand New Online Workshop

Tag Template - News Hub PRO

Singapore, Mar 21, 2022 - (ACN Newswire) - Infocus International Group has introduced the brand new online workshop - Renewable Power Finance for Non-Finance Professionals and it will be commencing live on the 20th of April 2022.

Tag Template - News Hub PRO

This popular course is intended as a time-efficient primer for those from a non-financial background, who wish to better "read" financial models & analyses presented to them, and to understand the variables which most influence renewable power project investment decisions.

Attendees will receive clear explanations of the common elements of a power project financial model, the key terminologies, and the changing economic and market context in which renewable power business plans must exist (and create financial returns).

The course will highlight the key financial inputs and outputs, without swamping those who lack a financial background in unnecessary detail or complexity. It will thus enable people from a variety of non-finance job roles - from engineering to project development to marketing - to better understand how economic and investment considerations influence, and are influenced by, their own activities.

A provided Excel cash flow model plus numerous other handouts will help with revision and cementation of learning long after the course has been completed.

Course Sessions

1. 'Reading' a project cash flow model
2. Risks, returns, and the costs of finance
3. The changing value of electricity
4. Power project business cases and profitability

Among the key points to be addressed

- Learn to speak the language of finance, to better interact with investors and business case developers
- Understand how to 'read' a financial analysis sheet, without being swamped by the minutiae and detail
- Take away an Excel cash flow sheet which you can use to revise and solidify your learning
- Learn how project risks feed through to financing costs and energy price competitiveness
- Analyse which internal project variables and external market factors are most important to financial outcomes
- Explore the financial considerations of trends such as multiple revenue streams and energy storage
- Examine the balances of risks and returns, at various stages in a project's life cycle
- Understand the relevance of metrics such as 'LCOE', 'WACC' & 'DSCR' in business planning
- Quantify how key market trends are impacting renewable power business cases, risks and returns

Want to learn more?

Simply email to emilia@infocusinternational.com or call +65 6325 0210 to obtain your FREE COPY of event brochure. For more information, please visit https://www.infocusinternational.com/renewable-power-finance.

About Infocus International Group

Infocus International is a global business intelligence provider of strategic information and professional services for diverse business communities.

Infocus International recognises clients' needs and responds with innovative and result oriented programmes. All products are founded on high value content in diverse subject areas, and the highest level of quality is ensured through intensive and in-depth market research from local and international insights.

Emilia Mok
Tel: +65 6325 0210
Email: emilia@infocusevent.com
Website: www.infocusinternational.com

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comInfocus International Group has introduced the brand new online workshop - Renewable Power Finance for Non-Finance Professionals and it will be commencing live on the 20th of April 2022.

How the COVID crisis caused K-12 to rethink testing

Educators are concerned that summative assessments make students anxious, and they want to move to a more balanced testing approachThe pandemic reignited the debate over shifting away from high-stakes testing to a more balanced assessment approach that’s part of the regular instructional cycle.

Is Spotify Heading To NFTs? Recent Job Postings Suggest So

Tag Template - News Hub PRO

Music NFTs are not a new thing, but music NFTs with Spotify is something else. Spotify, the world’s largest music streaming service, is eyeing a new opportunity to hop on the NFT bandwagon. The music streaming service recently posted two job listings for senior engineers to work on early-stage Web3 products. Spotify Plans To Add [...]

The post Is Spotify Heading To NFTs? Recent Job Postings Suggest So appeared first on Blockonomi.

PlayZap: The P2E Revolution has Begun

With the great changes that occurred in the DeFi world in 2021 and 2022, a new BTC ATH and with the mainstream adoption of non-standard crypto assets, the biggest revolution wasn’t even one that strictly happened in the blockchain tech niche. Bigger than NFTs, bigger than the Meta, the P2E revolution as an idea is...

The post PlayZap: The P2E Revolution has Begun appeared first on Live Bitcoin News.

NFTs will empower musicians to take back control

This surge in NFT sales can partly be attributed to the increased demand for crypto art and collectables.

The post NFTs will empower musicians to take back control appeared first on CryptoSlate.

ScreenPro Announces Growth in Covid Testing

Though the Covid environment is changing, testing is strong with a 50% increase in added productions compared to February and over 20% in weekly growth this month.
Tag Template - News Hub PRO

Recent articles

spot_img